Acute Disseminated Demyelination Treatment Market Analysis by Treatment Type {Corticosteroids, Immunoglobulin IVIg Therapy, Plasmapheresis }; End User (Hospitals, Clinics, Ambulatory Surgical Centers) – Global Supply & Demand Analysis & Opportunity Outlook 2023 – 2035
Buy Now Report ID: 4933 | Published Date: May 03, 2023
Acute Disseminated Demyelination Treatment Market size is estimated to reach ~USD 22 billion by the end of 2035 by growing at a CAGR of ~5% over the forecast period, i.e., 2023 – 2035. In addition to this, in the year 2022, the market size of acute disseminated demyelination treatment was ~USD 10 billion. The growth of this market can be attributed to the growing prevalence of acute disseminated demyelination disease worldwide with the rise in some recorded cases in recent times. As per our estimations, acute disseminated demyelination is expected to occur in approximately 0.8-2.0 cases per 100,000 individuals per year. Acute disseminated demyelination is more common in children and occurs more frequently in males than females.
Moreover, the rising prevalence of autoimmune diseases such as multiple sclerosis (MS) and neuromyelitis optica spectrum disorder (NMOSD) has increased the demand for acute disseminated demyelination treatment. The National Multiple Sclerosis Society reports that the prevalence of MS is increasing worldwide, affecting an estimated 2.8 million people worldwide. NMOSD is becoming more common, especially in Asia, with a prevalence of 0.05–10 per 100,000 people.
|
Base Year |
2022 |
|
Forecast Year |
2023 – 2035 |
|
CAGR |
~5% |
|
Base Year Market Size (2022) |
~USD 10 billion |
|
Forecast Year Market Size (2035) |
~USD 22 billion |
|
Regional Synopsis |
|
Growth Drivers
Challenges
The global acute disseminated demyelination treatment market is segmented and analyzed for demand and supply by treatment type into corticosteroids, immunoglobulin (IVIg) therapy, plasmapheresis, and others. Out of these, the corticosteroids segment is anticipated to hold the largest market share by the end of 2035. This can be attributed on the account of widespread acceptance of intravenous corticosteroids as first-line treatment for this condition. Studies have shown that high-dose corticosteroids can reduce inflammation and improve clinical outcomes in patients with ADEM.
The global market is segmented and analyzed for demand and supply by end-user into hospitals, clinics, ambulatory surgical centers, and others. Out of these, the hospital segment is anticipated to hold the largest market share by the end of 2035. Hospitals offer a variety of treatment options for acute disseminated demyelination patients, including high-dose corticosteroids, intravenous immunoglobulins, and plasmapheresis. In severe cases, patients may require hospitalization for monitoring and supportive care. The hospital also offers diagnostic services for acute disseminated demyelination patients, such as MRI scans, spinal taps, and blood tests. These tests are essential in diagnosing acute disseminated demyelination and monitoring disease progression. The hospital employs a variety of medical professionals trained in diagnosing and treating neurological disorders, including neurologists, neurosurgeons, and neurointensive care specialists. These professionals play an important role in the care of acute disseminated demyelination ADEM patients.
Our in-depth analysis of the global acute disseminated demyelination treatment market includes the following segments:
|
By Treatment Type |
|
|
By End User |
|
The market in North America is predicted to gather the largest share over the forecast period, which can be credited to the high healthcare expenditure, and increasing research and development activities to develop an effective treatment for acute disseminated demyelination in the region. As per the National Health Expenditure Account (NHEA), total healthcare spending in the United States grew 4.6 percent in 2019, reaching USD 3.8 trillion or USD 11,582 per person. As a share of the nation's gross domestic product (GDP), health spending accounted for 17.7 percent. North America has a well-established medical infrastructure that includes advanced diagnostic and therapeutic technologies. This infrastructure is designed to support the growth of the market. The United States in particular is one of the world's most expensive countries for healthcare. This high level of spending is estimated to support the growth of the market in North America.
The market in the Asia Pacific is estimated to witness noteworthy over the forecast period on the back of the large patient pool, rising developments in healthcare facilities in emerging economies namely China and India, and growing government investments to improve healthcare infrastructure in the region. The rising presence of this health disorder in the region and growing awareness about this health problem among healthcare professionals in the Asia-Pacific region is expected to drive the growth of the market in the Asia-Pacific region. This area is home to several significant corporations that are further making investments in R&D to create fresh, efficient therapies for acute disseminated demyelination. In addition to pharmaceutical firms, the Asia Pacific region is home to numerous research organizations, hospitals, clinical trials, and research studies on acute disseminated demyelination treatment. This is anticipated to spur commercial innovation and result in the creation of novel treatment choices for acute disseminated demyelination patients. Governments and private organizations in the Asia-Pacific region are increasing their investment in healthcare infrastructure and technology, which is expected to boost the growth of the acute disseminated demyelination treatment market.
The market in the Europe region is anticipated to hold a significant market share in the forecast period. ADEM is a rare autoimmune disease that affects the central nervous system and can have serious long-term consequences if left untreated. European governments and private organizations are increasing their investment in medical infrastructure and technology, which is expected to drive the growth of the market. The market for acute disseminated demyelination treatment in Europe is influenced by a number of variables, including the rising incidence of neurological illnesses, the rising desire for efficient therapies, and developments in medical technology. Government programs to upgrade the healthcare system, rising healthcare costs, and rising public knowledge of the condition are further variables that have an impact on the market.
In 2023, market players might incur losses due to huge gap in currency translation followed by contracting revenues, shrinking profit margins & cost pressure on logistics and supply chain.
Controlling Inflation has become the first priority for global economies from last quarter of 2022 and to be followed in 2023. With skewed economic situations, rise in interest rate by governments to control spending and inflation, spiked oil and gas prices, high inflation, geo-political issues including U.S. & China trade war, Russia-Ukraine conflict to intensify the global economic issues.
The interest rates in the U.S. may be less sensitive in 2023 as compared to 2022; sigh of relief for businesses. Positive business sentiments, healthy business balance sheets, growth in construction spending (private construction value in 2022 stood at $1,429.2 billion, 11.7 percent (±1.0 percent) above the $1,279.5 billion spent in 2021, Residential construction in 2022 was $899.1 billion, up by 13.3 percent (±2.1 percent) from $793.7 billion in 2021, non-residential construction touched $530.1 billion, 9.1 percent (±1.0 percent) above the $485.8 billion in 2021.) showcases minimal impact of recession in the country.
Similarly, spiked spending in the European and major Asia economics including, India, China & Japan to showcase less impact on the global demand.
Author Credits: Radhika Gupta, Shivam Bhutani
Ans: The major factors driving the market growth are the increasing prevalence of autoimmune diseases across the globe and the rising number of cases of acute disseminated demyelination.
Ans: The market size of acute disseminated demyelination treatment is anticipated to attain a CAGR of ~5% over the forecast period, i.e., 2023 – 2035.
Ans: Poor health infrastructure in underdeveloped nations is estimated to hamper market growth.
Ans: North America is estimated to create notable growth opportunities for market growth over the forecast period.
Ans: The major players in the market are Pfizer, Inc., Johnson & Johnson Service, Inc., Novartis AG, Merck & Co. GmbH, and Others.
Ans: The company profiles are selected based on the revenues generated from the product segment, the geographical presence of the company which determines the revenue generating capacity as well as the new products being launched into the market by the company.
Ans: The market is segmented by treatment, end user, and region.
Ans: The hospital segment is anticipated to garner the largest market size by the end of 2035 and display significant growth opportunities.
Submit Your Request For Proposal (RFP)
